FDA在发生死亡和受伤事件后,对爱德华兹心脏瓣膜输送系统的问题提出警示

路透中文
Oct 16
FDA在发生死亡和受伤事件后,对<a href="https://laohu8.com/S/EW">爱德华兹</a>心脏瓣膜输送系统的问题提出警示

路透10月15日 - 美国食品药品监督管理局(FDA)周四就涉及爱德华生命科学公司(Edwards Lifesciences)某些 EW.N 输送系统的一起潜在高风险问题发出警告,该系统用于经导管二尖瓣置换术,此前已造成1人死亡、1人重伤。

FDA表示,爱德华生命科学公司已要求客户停止使用受影响的设备,并退回相关产品。

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10